Small-molecule inhibitors of the Myc oncoprotein

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1849, Issue 5, 2015, Pages 525-543

  Fletcher, Steven ^a,b   Prochownik, Edward V ^c,d,e  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cancer; Max; Myc; Protein protein interaction; Small molecule inhibitor; Transcription factor

Indexed keywords

BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; MAX PROTEIN, HUMAN; MYC PROTEIN; PROTEIN BINDING;

BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PROTEIN BINDING; PROTEIN INTERACTION MAPS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION;

EID: 84898707339     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2014.03.005     Document Type: Review

References (207)

1. Arvanitis C., Felsher D.W. Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Semin. Cancer Biol. 2006, 16:313-317.
2. Delgado M.D., León J. Myc roles in hematopoiesis and leukemia. Genes Cancer 2010, 1:605-616.
3. Koh C.M., Bieberich C.J., Dang C.V., Nelson W.G., Yegnasubramanian S., De Marzo A.M. MYC and prostate cancer. Genes Cancer 2010, 1:617-628.
4. Nesbit C.E., Tersak J.M., Prochownik E.V. MYC oncogenes and human neoplastic disease. Oncogene 1999, 18:3004-3016.
5. Pelengaris S., Khan M. The many faces of c-MYC. Arch. Biochem. Biophys. 2003, 416:129-136.
6. Xu J., Chen Y., Olopade O.I. MYC and breast cancer. Genes Cancer 2010, 1:629-640.
7. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
8. Fukazawa T., Maeda Y., Matsuoka J., Yamatsuji T., Shigemitsu K., Morita I., Faiola F., Durbin M.L., Soucek L., Naomoto Y. Inhibition of Myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc. Anticancer Res. 2010, 30:4193-4200.
9. Soucek L., Whitfield J., Martins C.P., Finch A.J., Murphy D.J., Sodir N.M., Karnezis A.N., Swigart L.B., Nasi S., Evan G.I. Modelling Myc inhibition as a cancer therapy. Nature 2008, 455:679-683.
10. Soucek L., Whitfield J.R., Sodir N.M., Massó-Vallés D., Serrano E., Karnezis A.N., Swigart L.B., Evan G.I. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. 2013, 27:504-513.
11. Wang H., Mannava S., Grachtchouk V., Zhuang D., Soengas M.S., Gudkov A.V., Prochownik E.V., Nikiforov M.A. c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene 2008, 27:1905-1915.
12. Lefevre G., Calipel A., Mouriaux F., Hecquet C., Malecaze F., Mascarelli F. Opposite long-term regulation of c-Myc and p27Kip1 through overactivation of Raf-1 and the MEK/ERK module in proliferating human choroidal melanoma cells. Oncogene 2003, 22:8813-8822.
13. Sodir N.M., Swigart L.B., Karnezis A.N., Hanahan D., Evan G.I., Soucek L. Endogenous Myc maintains the tumor microenvironment. Genes Dev. 2011, 25:907-916.
14. Zhuang D., Mannava S., Grachtchouk V., Tang W.H., Patil S., Wawrzyniak J.A., Berman A.E., Giordano T.J., Prochownik E.V., Soengas M.S., Nikiforov M.A. c-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene 2008, 27:6623-6634.
15. Sears R., Nuckolls F., Haura E., Taya Y., Tamai K., Nevins J.R. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000, 14:2501-2514.
16. Shachaf C.M., Kopelman A.M., Arvanitis C., Karlsson A., Beer S., Mandl S., Bachmann M.H., Borowsky A.D., Ruebner B., Cardiff R.D., Yang Q., Bishop J.M., Contag C.H., Felsher D.W. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004, 431:1112-1117.
17. Wu C.H., van Riggelen J., Yetil A., Fan A.C., Bachireddy P., Felsher D.W. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:13028-13033.
18. Berg T. Inhibition of transcription factors with small organic molecules. Curr. Opin. Chem. Biol. 2008, 12:464-471.
19. Prochownik E.V., Vogt P.K. Therapeutic targeting of Myc. Genes Cancer 2010, 1:650-659.
20. Bisen A., Claxton D.F. Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms. Adv. Exp. Med. Biol. 2013, 779:179-196.
21. Kudchadkar R.R., Smalley K.S., Glass L.F., Trimble J.S., Sondak V.K. Targeted therapy in melanoma. Clin. Dermatol. 2013, 31:200-208.
22. Kim J.W., Gao P., Liu Y.C., Semenza G.L., Dang C.V. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol. Cell. Biol. 2007, 27:7381-7393.
23. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
24. Nyberg P., Salo T., Kalluri R. Tumor microenvironment and angiogenesis. Front. Biosci. 2008, 13:6537-6553.
25. Pello O.M., De Pizzol M., Mirolo M., Soucek L., Zammataro L., Amabile A., Doni A., Nebuloni M., Swigart L.B., Evan G.I., Mantovani A., Locati M. Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood 2012, 119:411-421.
26. Pello O.M., Chèvre R., Laoui D., De Juan A., Lolo F., Andrés-Manzano M.J., Serrano M., Van Ginderachter J.A., Andrés V. In vivo inhibition of c-MYC in myeloid cells impairs tumor-associated macrophage maturation and pro-tumoral activities. PLoS One 2012, 7:e45399.
27. Shchors K., Shchors E., Rostker F., Lawlor E.R., Brown-Swigart L., Evan G.I. The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes Dev. 2006, 20:2527-2538.
28. Karagiannis G.S., Poutahidis T., Erdman S.E., Kirsch R., Riddell R.H., Diamandis E.P. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol. Cancer Res. 2012, 10:1403-1418.
29. Orimo A., Weinberg R.A. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006, 5:1597-1601.
30. Baudino T.A., McKay C., Pendeville-Samain H., Nilsson J.A., Maclean K.H., White E.L., Davis A.C., Ihle J.N., Cleveland J.L. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 2002, 16:2530-2543.
31. He C., Hu H., Braren R., Fong S.Y., Trumpp A., Carlson T.R., Wang R.A. c-Myc in the hematopoietic lineage is crucial for its angiogenic function in the mouse embryo. Development 2008, 135:2467-2477.
32. Whitfield J.R., Soucek L. Tumor microenvironment: becoming sick of Myc. Cell. Mol. Life Sci. 2012, 69:931-934.
33. Fieber W., Schneider M.L., Matt T., Kräutler B., Konrat R., Bister K. Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc. J. Mol. Biol. 2001, 307:1395-1410.
34. Harvey S.R., Porrini M., Stachl C., MacMillan D., Zinzalla G., Barran P.E. Small-molecule inhibition of c-MYC:MAX leucine zipper formation is revealed by ion mobility mass spectrometry. J. Am. Chem. Soc. 2012, 134:19384-19392.
35. Michel J., Cuchillo R. The impact of small molecule binding on the energy landscape of the intrinsically disordered protein c-Myc. PLoS One 2012, 7:e41070.
36. Dunker A.K., Silman I., Uversky V.N., Sussman J.L. Function and structure of inherently disordered proteins. Curr. Opin. Struct. Biol. 2008, 18:756-764.
37. Iakoucheva L.M., Brown C.J., Lawson J.D., Obradovic Z., Dunker A.K. Intrinsic disorder in cell-signaling and cancer-associated proteins. J. Mol. Biol. 2002, 323:573-584.
38. Uversky V.N., Oldfield C.J., Dunker A.K. Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling. J. Mol. Recognit. 2005, 18:343-384.
39. Uversky V.N., Oldfield C.J., Dunker A.K. Intrinsically disordered proteins in human diseases: Introducing the D(2) concept. Annu. Rev. Biophys. 2008, 37:215-246.
40. Romero P.R., Obradovic Z., Dunker A.K. The complexity of disorder. Biophys. J. 1999, 76. (Part 2 of 2:A1-A525).
41. Cumberworth A., Lamour G., Babu M.M., Gsponer J. Promiscuity as a functional trait: intrinsically disordered regions as central players of interactomes. Biochem. J. 2013, 454:361-369.
42. Radivojac P., Iakoucheva L.M., Oldfield C.J., Obradovic Z., Uversky V.N., Dunker A.K. Intrinsic disorder and functional proteomics. Biophys. J. 2007, 92:1439-1456.
43. Gunasekaran K., Tsai C.J., Kumar S., Zanuy D., Nussinov R. Extended disordered proteins: targeting function with less scaffold. Trends Biochem. Sci. 2003, 28:81-85.
44. Metallo S.J. Intrinsically disordered proteins are potential drug targets. Curr. Opin. Chem. Biol. 2010, 14:481-488.
45. Dyson H.J., Wright P.E. Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell Biol. 2005, 6:197-208.
46. Brown C.J., Johnson A.K., Dunker A.K., Daughdrill G.W. Evolution and disorder. Curr. Opin. Struct. Biol. 2011, 21:441-446.
47. Baudino T.A., Cleveland J.L. The Max network gone mad. Mol. Cell. Biol. 2001, 21:691-702.
48. Hurlin P.J., Steingrìmsson E., Copeland N.G., Jenkins N.A., Eisenman R.N. Mga, a dual-specificity transcription factor that interacts with Max and contains a T-domain DNA-binding motif. EMBO J. 1999, 18:7019-7028.
49. Wahlström T., Henriksson M. Mnt takes control as key regulator of the myc/max/mxd network. Adv. Cancer Res. 2007, 97:61-80.
50. Bao J., Zervos A.S. Isolation and characterization of Nmi, a novel partner of Myc proteins. Oncogene 1996, 12:2171-2176.
51. Gaubatz S., Imhof A., Dosch R., Werner O., Mitchell P., Buettner R., Eilers M. Transcriptional activation by Myc is under negative control by the transcription factor AP-2. EMBO J. 1995, 4:1508-1519.
52. Herkert B., Eilers M. Transcriptional repression: the dark side of Myc. Genes Cancer 2010, 1:580-586.
53. Hu J., Banerjee A., Gross D.J. Assembly of b/HLH/z proteins cMyc, Max and Mad1 with cognate DNA: importance of protein-protein and protein-DNA interactions. Biochemistry 2005, 44:11855-11863.
54. Nair S.K., Burley S.K. X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 2003, 112:193-205.
55. Lee C., Bae K., Edery I. PER and TIM inhibit the DNA binding activity of a Drosophila CLOCK-CYC/dBMAL1 heterodimer without disrupting formation of the heterodimer: a basis for circadian transcription. Mol. Cell. Biol. 1999, 19:5316-5325.
56. John M., Leppik R., Busch S.J., Granger-Schnarr M., Schnarr M. DNA binding of Jun and Fos bZip domains: homodimers and heterodimers induce a DNA conformational change in solution. Nucleic Acids Res. 1996, 24:4487-4494.
57. Sánchez M., Jennings P.A., Murre C. Conformational changes induced in Hoxb-8/Pbx-1 heterodimers in solution and upon interaction with specific DNA. Mol. Cell. Biol. 1997, 17:5369-5376.
58. Rohs R., Jin X., West S.M., Joshi R., Honig B., Mann R.S. Origins of specificity in protein-DNA recognition. Annu. Rev. Biochem. 2010, 79:233-269.
59. Muhle-Goll C., Nilges M., Pastore A. The leucine zippers of the HLH-LZ proteins Max and c-Myc preferentially form heterodimers. Biochemistry 1995, 34:13554-113564.
60. O'Shea E.K., Rutkowski R., Kim P.S. Mechanism of specificity in the Fos-Jun oncoprotein heterodimer. Cell 1992, 68:699-708.
61. Thompson K.S., Vinson C.R., Freire E. Thermodynamic characterization of the structural stability of the coiled-coil region of the bZIP transcription factor GCN4. Biochemistry 1993, 32:5491-5496.
62. Muhle-Goll C., Gibson T., Schuck P., Schubert D., Nalis D., Nilges M., Pastore A. The dimerization stability of the HLH-LZ transcription protein family is modulated by the leucine zippers: a CD and NMR study of TFEB and c-Myc. Biochemistry 1994, 33:11296-11306.
63. Clackson T., Wells J.A. A hot spot of binding energy in a hormone-receptor interface. Science 1995, 267:383-386.
64. Wells J.A. Binding in the growth hormone receptor complex. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:1-6.
65. Eberhardy S.R., Farnham P.J. Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter. J. Biol. Chem. 2002, 277:40156-40162.
66. Cowling V.H., Cole M.D. Mechanism of transcriptional activation by the Myc oncoproteins. Semin. Cancer Biol. 2006, 16:242-252.
67. Guccione E., Martinato F., Finocchiaro G., Luzi L., Tizzoni L., Dall' Olio V., Zardo G., Nervi C., Bernard L., Amati B. Myc-binding-site recognition in the human genome is determined by chromatin context. Nat. Cell Biol. 2006, 8:764-770.
68. Gargano B., Amente S., Majello B., Lania L. P-TEFb is a crucial co-factor for Myc transactivation. Cell Cycle 2007, 6:2031-2037.
69. Lin C.Y.,., Lovén J., Rahl P.B., Paranal R.M., Burge C.B., Bradner J.E., Lee T.I., Young R.A. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012, 151:56-67.
70. Nie Z., Hu G., Wei G., Cui K., Yamane A., Resch W., Wang R., Green D.R., Tessarollo L., Casellas R., Zhao K., Levens D. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 2012, 151:68-79.
71. Rahl P.B., Lin C.Y., Seila A.C., Flynn R.A., McCuine S., Burge C.B., Sharp P.A., Young R.A. c-Myc regulates transcriptional pause release. Cell 2010, 141:432-445.
72. Knoepfler P.S., Zhang X.Y., Cheng P.F., Gafken P.R., McMahon S.B., Eisenman R.N. Myc influences global chromatin structure. EMBO J. 2006, 25:2723-2734.
73. Faiola F., Wu Y.T., Pan S., Zhang K., Farina A., Martinez E. Max is acetylated by p300 at several nuclear localization residues. Biochem. J. 2007, 403:397-407.
74. Ikura T., Ogryzko V.V., Grigoriev M., Groisman R., Wang J., Horikoshi M., Scully R., Qin J., Nakatani Y. Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell 2000, 102:463-473.
75. Patel J.H., Du Y., Ard P.G., Phillips C., Carella B., Chen C.J., Rakowski C., Chatterjee C., Lieberman P.M., Lane W.S., Blobel G.A., McMahon S.B. The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Mol. Cell. Biol. 2004, 24:10826-10834.
76. Zhang K., Faiola F., Martinez E. Six lysine residues on c-Myc are direct substrates for acetylation by p300. Biochem. Biophys. Res. Commun. 2005, 336:274-280.
77. Marshall N.F., Price D.H. Purification of P-TEFb, a transcription factor required for the transition into productive elongation. J. Biol. Chem. 1995, 270:12335-12338.
78. Peng J., Zhu Y., Milton J.T., Price D.H. Identification of multiple cyclin subunits of human P-TEFb. Genes Dev. 1998, 12:755-762.
79. Maniatis T., Reed R. An extensive network of coupling among gene expression machines. Nature 2002, 416:499-506.
80. Sims R.J., Mandal S.S., Reinberg D. Recent highlights of RNA-polymerase-II-mediated transcription. Curr. Opin. Cell Biol. 2004, 16:263-271.
81. Bentley D.L. Rules of engagement: co-transcriptional recruitment of pre-mRNA processing factors. Curr. Opin. Cell Biol. 2005, 17:251-256.
82. Brès V., Yoh S.M., Jones K.A. The multi-tasking P-TEFb complex. Curr. Opin. Cell Biol. 2008, 20:334-340.
83. Pirngruber J., Shchebet A., Johnsen S.A. Insights into the function of the human P-TEFb component CDK9 in the regulation of chromatin modifications and co-transcriptional mRNA processing. Cell Cycle 2009, 8:3636-3642.
84. Zeng I., Zhou M.-M. Bromodomain an acetyl lysine binding domain. FEBS Lett. 2002, 513:124-128.
85. Jang M.K., et al. The bromodomain protein Brd4 is a positive regulatory component of P TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell 2005, 19:523-534.
86. Yang Z., Yik J.H., Chen R., He N., Jang M.K., Ozato K., Zhou Q. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell 2005, 19:535-545.
87. Wu S.Y., Chiang C.M. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J. Biol. Chem. 2007, 282:13141-13145.
88. Yang Z., He N., Zhou Q. Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. Mol. Cell. Biol. 2008, 28:967-976.
89. Chiang C.M. Brd4 engagement from chromatin targeting to transcriptional regulation: selective contact with acetylated histone H3 and H4. F1000. Biol. Rep. 2009, 1:98.
90. Schröder S., Cho S., Zeng L., Zhang Q., Kaehlcke K., Mak L., Lau J., Bisgrove D., Schnölzer M., Verdin E., Zhou M.M., Ott M. Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes. J. Biol. Chem. 2012, 287:1090-1099.
91. Seila A.C., Calabrese J.M., Levine S.S., Yeo G.W., Rahl P.B., Flynn R.A., Young R.A., Sharp P.A. Divergent transcription from active promoters. Science 2008, 322:1849-1851.
92. Cho S., Schroeder S., Ott M. CYCLINg through transcription: posttranslational modifications of P-TEFb regulate transcription elongation. Cell Cycle 2010, 9:1697-1705.
93. Lenasi T., Barboric M. P-TEFb stimulates transcription elongation and pre-mRNA splicing through multilateral mechanisms. RNA Biol. 2010, 7:145-150.
94. Patel M.C., Debrosse M., Smith M., Dey A., Huynh W., Sarai N., Heightman T.D., Tamura T., Ozato K. BRD4 coordinates recruitment of pause release factor P-TEFb and the pausing complex NELF/DSIF to regulate transcription elongation of interferon-stimulated genes. Mol. Cell. Biol. 2013, 33:2497-2507.
95. Yamaguchi Y., Shibata H., Handa H. Transcription elongation factors DSIF and NELF: promoter-proximal pausing and beyond. Biochim. Biophys. Acta 2013, 1829:98-104.
96. Secombe J., Li L., Carlos L., Eisenman R.N. The Trithorax group protein Lid is a trimethyl histone H3K4 demethylase required for Myc-induced cell growth. Genes Dev. 2007, 21:537-551.
97. Secombe J., Eisenman R.N. The function and regulation of the JARID1 family of histone H3 lysine 4 demethylases: the Myc connection. Cell Cycle 2007, 6:1324-1328.
98. Santos-Rosa H., Schneider R., Bannister A.J., Sherriff J., Bernstein B.E., Emre N.C., Schreiber S.L., Mellor J., Kouzarides T. Active genes are tri-methylated at K4 of histone H3. Nature 2002, 419:407-411.
99. Schübeler D., MacAlpine D.M., Scalzo D., Wirbelauer C., Kooperberg C., van Leeuwen F., Gottschling D.E., O'Neill L.P., Turner B.M., Delrow J., Bell S.P., Groudine M. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev. 2004, 18:1263-1271.
100. Kim T.H., Barrera L.O., Zheng M., Qu C., Singer M.A., Richmond T.A., Wu Y., Green R.D., Ren B. A high-resolution map of active promoters in the human genome. Nature 2005, 436:876-880.
101. Szutorisz H., Canzonetta C., Georgiou A., Chow C.M., Tora L., Dillon N. Formation of an active tissue-specific chromatin domain initiated by epigenetic marking at the embryonic stem cell stage. Mol. Cell. Biol. 2005, 25:1804-1820.
102. Frank S.R., Schroeder M., Fernandez P., Taubert S., Amati B. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev. 2001, 15:2069-2082.
103. Zuber J., Shi J., Wang E., Rappaport A.R., Herrmann H., Sison E.A., Magoon D., Qi J., Blatt K., Wunderlich M., Taylor M.J., Johns C., Chicas A., Mulloy J.C., Kogan S.C., Brown P., Valent P., Bradner J.E., Lowe S.W., Vakoc C.R. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.
104. Bhatia K., Huppi K., Spangler G., Siwarski D., Iyer R., Magrath I. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat. Genet. 1993, 5:56-61.
105. Yano T., Sander C.A., Clark H.M., Dolezal M.V., Jaffe E.S., Raffeld M. Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma. Oncogene 1993, 8:2741-2748.
106. Clark H.M., Yano T., Otsuki T., Jaffe E.S., Shibata D., Raffeld M. Mutations in the coding region of c-MYC in AIDS-associated and other aggressive lymphomas. Cancer Res. 1994, 54:3383-3386.
107. Bahram F., von der Lehr N., Cetinkaya C., Larsson J.G. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 2000, 95:2104-2110.
108. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 399:1546-1558.
109. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996, 2:561-566.
110. Dang C.V. MYC, microRNAs and glutamine addiction in cancers. Cell Cycle 2009, 8:3243-3245.
111. Weinstein I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002, 297:63-64.
112. Jain M., Arvanitis C., Chu K., Dewey W., Leonhardt E., Trinh M., Sundberg C.D., Bishop J.M., Felsher D.W. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002, 297:102-104.
113. Murphy D.J., Junttila M.R., Pouyet L., Karnezis A., Shchors K., Bui D.A., Brown-Swigart L., Johnson L., Evan G.I. Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 2008, 14:447-457.
114. Ward P.S., Thompson C.B. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012, 21:297-308.
115. Wise D.R., DeBerardinis R.J., Mancuso A., Sayed N., Zhang X.Y., Pfeiffer H.K., Nissim I., Daikhin E., Yudkoff M., McMahon S.B., Thompson C.B. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:18782-18787.
116. Jones S., Thornton J.M. Principles of protein-protein interactions. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:13-20.
117. Stites W.E. Protein-protein interactions: interface structure, binding thermodynamics, and mutational analysis. Chem. Rev. 1997, 97:1233-1250.
118. Lo Conte L., Chothia C., Janin J. The atomic structure of protein-protein recognition sites. J. Mol. Biol. 1999, 285:2177-2198.
119. Arkin M.R., Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 2004, 3:301-317.
120. Cheng Y., LeGall T., Oldfield C.J., Mueller J.P., Van Y.Y., Romero P., Cortese M.S., Uversky V.N., Dunker A.K. Rational drug design via intrinsically disordered protein. Trends Biotechnol. 2006, 24:435-442.
121. Koehler A.N. A complex task? Direct modulation of transcription factors with small molecules. Curr. Opin. Chem. Biol. 2010, 14:331-340.
122. Meireles L.M., Mustata G. Discovery of modulators of protein-protein interactions: current approaches and limitations. Curr. Top. Med. Chem. 2011, 11:248-257.
123. Gårdsvoll H., Danø K., Ploug M. Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis. J. Biol. Chem. 1999, 274:37995-38003.
124. Patel S., Player M.R. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer. Expert. Opin. Investig. Drugs 2008, 17:1865-1882.
125. Billard C. BH3 Mimetics: status of the field and new developments. Mol. Cancer Ther. 2013, 12:1691-1700.
126. Yap J.L., Chauhan J., Jung K.-Y., Chen L., Prochownik E.V., Fletcher S. Small-molecule inhibitors of dimeric transcription factors: antagonism of protein-protein and protein-DNA interactions. Med. Chem. Commun. 2012, 3:541-551.
127. Lanning M., Fletcher S. Recapitulating the α-helix: nonpeptidic, low-molecular-weight ligands for the modulation of helix-mediated protein-protein interactions. Future Med. Chem. 2013, 5:2157-2174.
128. Adler M.J., Jamieson A.G., Hamilton A.D. Hydrogen-bonded synthetic mimics of protein secondary structure as disruptors of protein-protein interactions. Curr. Top. Microbiol. Immunol. 2011, 348:1-23.
129. Berg T., Cohen S.B., Desharnais J., Sonderegger C., Maslyar D.J., Goldberg J., Boger D.L., Vogt P.K. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:3830-3835.
130. Yin X., Giap C., Lazo J.S., Prochownik E.V. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 2003, 22:6151-6159.
131. Bowman T., Broome M.A., Sinibaldi D., Wharton W., Pledger W.J., Sedivy J.M., Irby R., Yeatman T., Courtneidge S.A., Jove R. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:7319-7324.
132. Shi J., Stover J.S., Whitby L.R., Vogt P.K., Boger D.L. Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation. Bioorg. Med. Chem. Lett. 2009, 19:6038-6041.
133. Xu Y., Shi J., Yamamoto N., Moss J.A., Vogt P.K., Janda K.D. A credit-card library approach for disrupting protein-protein interactions. Bioorg. Med. Chem. 2006, 14:2660-2673.
134. Kiessling A., Sperl B., Hollis A., Eick D., Berg T. Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. Chem. Biol. 2006, 13:745-751.
135. Hopewell R., Ziff E.B. The nerve growth factor-responsive PC12 cell line does not express the Myc dimerization partner Max. Mol. Cell. Biol. 1995, 15:3470-3478.
136. Kiessling A., Wiesinger R., Sperl B., Berg T. Selective inhibition of c-Myc/Max dimerization by a pyrazolo[1,5-a]pyrimidine. ChemMedChem 2007, 2:627-630.
137. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001, 46:3-26.
138. Mateyak M.K., Obaya A.J., Adachi S., Sedivy J.M. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ. 1997, 8:1039-1048.
139. Wang H., Hammoudeh D.I., Follis A.V., Reese B.E., Lazo J.S., Metallo S.J., Prochownik E.V. Improved low molecular weight Myc-Max inhibitors. Mol. Cancer Ther. 2007, 6:2399-2408.
140. Follis A.V., Hammoudeh D.I., Wang H., Prochownik E.V., Metallo S.J. Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chem. Biol. 2008, 15:1149-1155.
141. Obradovic Z., Peng K., Vucetic S., Radivojac P., Dunker A.K. Exploiting heterogeneous sequence properties improves prediction of protein disorder. Proteins 2000, 61(Suppl. 7):176-182.
142. Hammoudeh D.I., Follis A.V., Prochownik E.V., Metallo S.J. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J. Am. Chem. Soc. 2009, 131:7390-7401.
143. Follis A.V., Hammoudeh D.I., Daab A.T., Metallo S.J. Small-molecule perturbation of competing interactions between c-Myc and Max. Bioorg. Med. Chem. Lett. 2009, 19:807-810.
144. Yap J.L., Wang H., Hu A., Chauhan J., Jung K.-Y., Gharavi R.B., Prochownik E.V., Fletcher S. Pharmacophore identification of c-Myc inhibitor 10074-G5. Bioorg. Med. Chem. Lett. 2013, 23:370-374.
145. Wang H., Chauhan J., Hu A., Pendleton K., Yap J.L., Sabato P.E., Jones J.W., Perri M., Yu J., Cione E., Kane M.A., Fletcher S., Prochownik E.V. Disruption of Myc-Max heterodimerization with improved cell-penetrating analogs of the small molecule 10074-G5. Oncotarget 2013, 4:936-947.
146. Cuchillo R., Michel J. Mechanisms of small-molecule binding to intrinsically disordered proteins. Biochem. Soc. Trans. 2012, 40:1004-1008.
147. Barducci A., Bonomi M., Parrinello M. Metadynamics. Wiley Interdiscip. Rev. Comput. Mol. Sci. 2011, 1:826-843.
148. Piana S., Laio A. A bias-exchange approach to protein folding. J. Phys. Chem. B 2007, 111:4553-4559.
149. Zirath H., Frenzel A., Oliynyk G., Segerström L., Westermark U.K., Larsson K., Munksgaard Persson M., Hultenby K., Lehtiö J., Einvik C., Påhlman S., Kogner P., Jakobsson P.J., Henriksson M.A. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:10258-10263.
150. Li F., Wang Y., Zeller K.I., Potter J.J., Wonsey D.R., O'Donnell K.A., Kim J.W., Yustein J.T., Lee L.A., Dang C.V. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol. Cell. Biol. 2005, 25:6225-6234.
151. Graves J.A., Wang Y., Sims-Lucas S., Cherok E., Rothermund K., Branca M.F., Elster J., Beer-Stolz D., Van Houten B., Vockley J., Prochownik E.V. Mitochondrial structure, function and dynamics are temporally controlled by c-Myc. PLoS One 2012, 7:e37699.
152. Holien T., Våtsveen T.K., Hella H., Waage A., Sundan A. Addiction to c-MYC in multiple myeloma. Blood 2012, 120:2450-2453.
153. Chng W.J., Huang G.F., Chung T.H., Ng S.B., Gonzalez-Paz N., Troska-Price T., Mulligan G., Chesi M., Bergsagel P.L., Fonseca R. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011, 25:1026-1035.
154. Hideshima T., Mitsiades C., Tonon G., Richardson P.G., Anderson K.C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. Cancer 2007, 7:585-598.
155. Shou Y., Martelli M.L., Gabrea A., Qi Y., Brents L.A., Roschke A., Dewald G., Kirsch I.R., Bergsagel P.L., Kuehl W.M. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:228-233.
156. Guo J., Parise R.A., Joseph E., Egorin M.J., Lazo J.S., Prochownik E.V., Eiseman J.L. Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z, E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother. Pharmacol. 2009, 63:615-625.
157. Clausen D.M., Guo J., Parise R.A., Beumer J.H., Egorin M.J., Lazo J.S., Prochownik E.V., Eiseman J.L. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. J. Pharmacol. Exp. Ther. 2010, 335:715-727.
158. Weiss W.A., Aldape K., Mohapatra G., Feuerstein B.G., Bishop J.M. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 1997, 16:2985-2995.
159. Rahman S., Sowa M.E., Ottinger M., Smith J.A., Shi Y., Harper J.W., Howley P.M. The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Mol. Cell. Biol. 2011, 31:2641-2652.
160. Vervoorts J., Lüscher-Firzlaff J.M., Rottmann S., Lilischkis R., Walsemann G., Dohmann K., Austen M., Lüscher B. Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP. EMBO Rep. 2003, 4:484-490.
161. French C.A., Miyoshi I., Aster J.C., Kubonishi I., Kroll T.G., Dal Cin P., Vargas S.O., Perez-Atayde A.R., Fletcher J.A. BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19). Am. J. Pathol. 2001, 159:1987-1992.
162. French C.A., Miyoshi I., Kubonishi I., Grier H.E., Perez-Atayde A.R., Fletcher J.A. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 2003, 63:304-307.
163. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., Philpott M., Munro S., McKeown M.R., Wang Y., Christie A.L., West N., Cameron M.J., Schwartz B., Heightman T.D., La Thangue N., French C.A., Wiest O., Kung A.L., Knapp S., Bradner J.E. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
164. S. Miyoshi, S. Ooike, K. Iwata, H. Hikawa, K. Sugaraha, International Patent No. PCT/JP2008/073864 (WO/2009/084693) (2009).
165. Hewings D.S., Rooney T.P., Jennings L.E., Hay D.A., Schofield C.J., Brennan P.E., Knapp S., Conway S.J. Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions. J. Med. Chem. 2012, 55:9393-9413.
166. Mertz J.A., Conery A.R., Bryant B.M., Sandy P., Balasubramanian S., Mele D.A., Bergeron L., Sims R.J. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:16669-16674.
167. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., Chesi M., Schinzel A.C., McKeown M.R., Heffernan T.P., Vakoc C.R., Bergsagel P.L., Ghobrial I.M., Richardson P.G., Young R.A., Hahn W.C., Anderson K.C., Kung A.L., Bradner J.E., Mitsiades C.S. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
168. McMillin D.W., Delmore J., Weisberg E., Negri J.M., Geer D.C., Klippel S., Mitsiades N., Schlossman R.L., Munshi N.C., Kung A.L., Griffin J.D., Richardson P.G., Anderson K.C., Mitsiades C.S. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat. Med. 2010, 16:483-489.
169. Ott C.J., Kopp N., Bird L., Paranal R.M., Qi J., Bowman T., Rodig S.J., Kung A.L., Bradner J.E., Weinstock D.M. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012, 120:2843-2852.
170. Chen I.M., Harvey R.C., Mullighan C.G., Gastier-Foster J., Wharton W., Kang H., Borowitz M.J., Camitta B.M., Carroll A.J., Devidas M., Pullen D.J., Payne-Turner D., Tasian S.K., Reshmi S., Cottrell C.E., Reaman G.H., Bowman W.P., Carroll W.L., Loh M.L., Winick N.J., Hunger S.P., Willman C.L. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 2012, 119:3512-3522.
171. Segura M.F., Fontanals-Cirera B., Gaziel-Sovran A., Guijarro M.V., Hanniford D., Zhang G., Gonzalez-Gomez P., Morante M., Jubierre L., Zhang W., Darvishian F., Ohlmeyer M., Osman I., Zhou M., Hernando E. BRD4 sustains proliferation and represents a new target for epigenetic therapy in melanoma. Cancer Res. 2013, 73:6264-6276.
172. Ugurel S., Thirumaran R.K., Bloethner S., Gast A., Sucker A., Mueller-Berghaus J., Rittgen W., Hemminki K., Becker J.C., Kumar R., Schadendorf D. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One 2007, 2:e236.
173. Kaelin W.G. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 2005, 5:689-698.
174. Nijman S.M., Friend S.H. Cancer. Potential of the synthetic lethality principle. Science 2013, 342:809-811.
175. Comen E.A., Robson M. Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer J. 2010, 16:48-52.
176. Kee Y., D'Andrea A.D. Molecular pathogenesis and clinical management of Fanconi anemia. J. Clin. Invest. 2012, 122:3799-3806.
177. Rottmann S., Wang Y., Nasoff M., Deveraux Q.L., Quon K.C. A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:15195-15200.
178. Welcker M., Clurman B.E. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 2008, 8:83-93.
179. Take Y., Kumano M., Teraoka H., Nishimura S., Okuyama A. DNA-dependent protein kinase inhibitor (OK-1035) suppresses p21 expression in HCT116 cells containing wild-type p53 induced by adriamycin. Biochem. Biophys. Res. Commun. 1996, 221:207-212.
180. Wang Y., Szekely L., Okan I., Klein G., Wiman K.G. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene 1993, 8:3427-3431.
181. Henriksson M., Selivanova G., Lindström M., Wiman K.G. Inactivation of Myc-induced p53-dependent apoptosis in human tumors. Apoptosis 2001, 6:133-137.
182. Feng Z., Hu W., Rajagopal G., Levine A.J. The tumor suppressor p53: cancer and aging. Cell Cycle 2008, 7:842-847.
183. Mo H., Henriksson M. Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:6344-6349.
184. Malumbres M., Barbacid M. Cell cycle kinases in cancer. Curr. Opin. Genet. Dev. 2007, 17:60-65.
185. Th'ng J.P., Wright P.S., Hamaguchi J., Lee M.G., Norbury C.J., Nurse P., Bradbury E.M. The FT210 cell line is a mouse G2 phase mutant with a temperature-sensitive CDC2 gene product. Cell 1990, 63:313-324.
186. Goga A., Yang D., Tward A.D., Morgan D.O., Bishop J.M. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat. Med. 2007, 13:820-827.
187. Deveraux Q.L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula S.M., Alnemri E.S., Salvesen G.S., Reed J.C. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998, 17:2215-2223.
188. O'Connor D.S., Grossman D., Plescia J., Li F., Zhang H., Villa A., Tognin S., Marchisio P.C., Altieri D.C. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:13103-13107.
189. Stone A., Sutherland R.L., Musgrove E.A. Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics. Crit. Rev. Oncog. 2012, 17:175-198.
190. Yang D., Liu H., Goga A., Kim S., Yuneva M., Bishop J.M. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:13836-13841.
191. van der Waal M.S., Hengeveld R.C., van der Horst A., Lens S.M. Cell division control by the chromosomal passenger complex. Exp. Cell Res. 2012, 318:1407-1420.
192. Yin X.Y., Grove L., Datta N.S., Long M.W., Prochownik E.V. c-Myc overexpression and p53 loss cooperate to promote genomic instability. Oncogene 1999, 18:1177-1184.
193. Yin X.Y., Grove L., Datta N.S., Katula K., Long M.W., Prochownik E.V. Inverse regulation of cyclin B1 by c-Myc and p53 and induction of tetraploidy by cyclin B1 overexpression. Cancer Res. 2001, 61:6487-6493.
194. Farag S.S. The potential role of Aurora kinase inhibitors in haematological malignancies. Br. J. Haematol. 2011, 155:561-579.
195. Kessler J.D., Kahle K.T., Sun T., Meerbrey K.L., Schlabach M.R., Schmitt E.M., Skinner S.O., Xu Q., Li M.Z., Hartman Z.C., Rao M., Yu P., Dominguez-Vidana R., Liang A.C., Solimini N.L., Bernardi R.J., Yu B., Hsu T., Golding I., Luo J., Osborne C.K., Creighton C.J., Hilsenbeck S.G., Schiff R., Shaw C.A., Elledge S.J., Westbrook T.F. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 2012, 335:348-353.
196. Dumontet C., Sikic B.I. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol. 1999, 17:1061-1070.
197. Efferth T., Dunstan H., Sauerbrey A., Miyachi H., Chitambar C.R. The anti-malarial artesunate is also active against cancer. Int. J. Oncol. 2001, 18:767-773.
198. Efferth T., Olbrich A., Bauer R. mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem. Pharmacol. 2002, 64:617-623.
199. Lu J.J., Meng L.H., Shankavaram U.T., Zhu C.H., Tong L.J., Chen G., Lin L.P., Weinstein J.N., Ding J. Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem. Pharmacol. 2010, 80:22-30.
200. Jiang H., Bower K.E., Beuscher A.E., Zhou B., Bobkov A.A., Olson AJ A.J., Vogt P.K. Stabilizers of the Max homodimer identified in virtual ligand screening inhibit Myc function. Mol. Pharmacol. 2009, 76:491-502.
201. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Biol. 1998, 19:1639-1662.
202. Sampson V.B., Rong N.H., Han J., Yang Q., Aris V., Soteropoulos P., Petrelli N.J., Dunn S.P., Krueger L.J. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res. 2007, 67:9762-9770.
203. Cairo S., Wang Y., de Reyniès A., Duroure K., Dahan J., Redon M.J., Fabre M., McClelland M., Wang X.W., Croce C.M., Buendia M.A. Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:20471-20476.
204. Chen Y., Jacamo R., Konopleva M., Garzon R., Croce C., Andreeff M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J. Clin. Invest. 2013, 123:2395-2407.
205. Akao Y., Nakagawa Y., Naoe T. Let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol. Pharm. Bull. 2006, 29:903-906.
206. Long X.B., Sun G.B., Hu S., Liang G.T., Wang N., Zhang X.H., Cao P.P., Zhen H.T., Cui Y.H., Liu Z. Let-7a microRNA functions as a potential tumor suppressor in human laryngeal cancer. Oncol. Rep. 2009, 22:1189-1195.
207. Liu Y., Yin B., Zhang C., Zhou L., Fan J. Hsa-let-7a functions as a tumor suppressor in renal cell carcinoma cell lines by targeting c-myc. Biochem. Biophys. Res. Commun. 2012, 417:371-375.